TOKYO, JAPAN - February 9, 2022 - Terumo Corporation (TSE: 4543) today announced that in conjunction with the new 5-Year Growth Strategy with a 10-Year Vision (GS26) starting next fiscal year, the company will implement a new Executive Officers' Management System effective from April 1, 2022 onwards. This new management system will redefine the responsibilities of both the Executive Officers representing the entire Terumo Group and the Executive Officers representing Terumo Corporation.
The current Executive Officers' Management System was implemented in 2002 with its structure built mainly around the headquarter in Japan . Since then, Terumo has rapidly expanded its business globally. The new Executive Officers' Management System will play a part to enhance Terumo Group's competitiveness on a global level and to achieve our visions defined in GS26.
The changes implemented in the new Executive Officers' Management System is as follows.
1. Establishment of Group Executive Officer (GEO)
Group Executive Officers will be responsible to set management directions and to discuss Terumo Group management strategies beyond business divisions and regions.
The GEO will be structured around Directors and Executive Officers such as the Chairman of the Board, the President and CEO, Company Presidents, Corporate Function Executives, CEOs of Major Business Subsidiaries, and Regional Representatives.
Furthermore, among the GEO structure, the Group Managing Executive Officer (GMEO) will take part in the Executive Management Meeting (EMM) as a core member to execute management strategies for the Terumo Group. By definition, the GMEOs must be a Managing Executive Officer/Senior Managing Executive Officer or higher.
2. Redefinition of Executive Officer (EO)
Executive Officers are those who are not part of GEO and is responsible for making decisions for their Company or Function.
In addition, the new Executive Officers' Management System clarifies each members' job description based on their position and responsibility. Appointment of each Executive Officer will be based on this clarified criteria and process. For Terumo Corporation in Japan, positions above managers will also implement the same methodology and approach.
With the new Executive Officers' Management System taking place, Terumo will strive towards realizing GS26 and further drive global growth.
Appendix: Executive Officers (As of April 1, 2022)
■Group Executive Officer: GEO
Group Managing Executive Officer: GMEO
[Chairman of the Board]
[President and CEO]
|Group Senior Managing Executive Officer||Hikaru Samejima||
Medical Care Solutions Company
|Group Senior Managing Executive Officer||Toshihiko Osada||
Cardiac and Vascular Company
|Group Managing Executive Officer||Antoinette Gawin||
Blood and Cell Technologies Company
|Group Senior Managing Executive Officer||Shoji Hatano|
|Group Managing Executive Officer||Kyo Nishikawa||
Chief Human Resources Officer (CHRO)
|Group Managing Executive Officer||Kazunori Hirose||
Chief Manufacturing Officer (CMO)
|Group Managing Executive Officer||Fumihisa Hirose||
General Manager, Strategic Planning Dept. and Chief Technology Officer (CTO)
Group Executive Officer: GEO
[CEOs of Major Business Subsidiaries]
|Group Executive Officer||James Rushworth||
President and CEO, Terumo Medical Corp.
|Group Executive Officer||Robert DeRyke||
President and CEO, Terumo Cardiovascular Systems Corp.
|Group Executive Officer||Carsten Schroeder||
President and CEO, MicroVention, Inc.
|Group Executive Officer||Erik Pomp||
President and CEO, Terumo Aortic
|Group Executive Officer||Hiroshi Nagumo||
Regional Representative, Americas
|Group Executive Officer||Probir Das||
Regional Representative, Asia Pacific and India
|Group Executive Officer||Norimasa Kunimoto||
Regional Representative, Europe, Middle East and Africa
|Group Executive Officer||Masayuki Maruta||
Regional Representative, China
|Group Executive Officer||Naoki Muto||
Chief Accounting and Financial Officer (CAFO)
|Senior Executive Officer||Tsuyoshi Tomita||
Division President, Hospital Care Solution Division, Medical Care Solutions Company
|Senior Executive Officer||Itaru Sakaguchi||
Chief Operations Officer (COO), Interventional Systems Division, Cardiac and Vascular Company
President, Terumo Yamaguchi Corp.
|Executive Officer||Takeshi Kuroo||
Senior Vice President, Surgical Business, Cardiac and Vascular Company
General Manager, HeartSheet Business Dept., Cardiac and Vascular Company
|Executive Officer||Hiroshi Yagi||
General Manager, Ashitaka Factory, Interventional Systems Division, Cardiac and Vascular Company
|Executive Officer||Noritsugu Fujita||
Division President, Pharmaceutical Solution Division, Medical Care Solutions Company
|Senior Executive Officer||Kazuhisa Senshu||
Chief Clinical and Regulatory Affairs Officer (CRAO)
|Executive Officer||Miho Mizuguchi||
Chief Legal Officer (CLO)
|Executive Officer||Tomoko Manabe||
General Manager, Terumo Medical Pranex
|Executive Officer||Keiji Takeda||
General Manager, Human Resources Dept.
|Executive Officer||Toshio Nakashima||
Chief Quality Officer (CQO)
|Executive Officer||Jin Nishizaki||
General Manager, Japan Sales Dept.
|Executive Officer||Hitoshi Hasegawa||
Chief Information Officer (CIO)
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.